CPA
CGEM icon

Capital Performance Advisors’s Cullinan Oncology CGEM Stock Holding History

Capital Performance Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13
Closed -$218 – 633
2024
Q3 		$218 Buy
+13
New +$231 ﹤0.01% 2536

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Performance Advisors's CGEM Position: Q4 2024 in Review

Capital Performance Advisors sold out of Cullinan Oncology (CGEM) in Q4 2024, closing a stake of 13 shares — an estimated $218 sold.

Capital Performance Advisors first reported a position in CGEM in Q3 2024 and held it in 1 quarter. The position peaked at $218 in Q3 2024. 146 funds tracked by Wall St. Rank hold CGEM as of Q4 2024.

  • Capital Performance Advisors reported no remaining Cullinan Oncology position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 13 Cullinan Oncology shares in Q4 2024, an estimated $218.
  • Capital Performance Advisors first reported a position in Cullinan Oncology in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Cullinan Oncology position peaked at $218 in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.